

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Wai Yuen Tong Medicine Holdings Limited.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

ANNOUNCEMENT

Despatch of the Circular relating to

VERY SUBSTANTIAL ACQUISITION

in relation to

possible voluntary conditional partial share exchange offer by

Kingston Securities Limited

on behalf of Gain Better Investments Limited,

a wholly-owned subsidiary of

Wai Yuen Tong Medicine Holdings Limited,

to acquire 1,463,835,000 shares in the capital of

LeRoi Holdings Limited

from the Independent LeRoi Shareholders,

Mandate to allot and issue new shares of Wai Yuen Tong Medicine Holdings Limited

and

MAJOR TRANSACTION

in relation to advance to LeRoi Holdings Limited

The Circular setting out, inter alia, (i) details of the Partial Share Exchange Offer and the information prescribed by the Listing Rules; (ii) details of the Loan Agreement and the transaction(s) contemplated thereunder; (iii) a letter from Nuada Limited containing its recommendation and advice to the board of directors of WYT in respect of the Partial Share Exchange Offer in accordance with Rule 2.4 of the Takeovers Code; and (iv) a notice of the SGM, together with a form of proxy for use at the SGM, will be despatched to the WYT Shareholders on 16 September 2009.

* *For identification purpose only*

Reference is made to the joint announcements issued by Wai Yuen Tong Medicine Holdings Limited (“WYT”) and LeRoi Holdings Limited dated 19 August 2009 and 28 August 2009 (the “**Joint Announcements**”) in relation to, amongst other matters, the Partial Share Exchange Offer and the Loan Agreement. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Joint Announcements.

DESPATCH OF THE CIRCULAR

The circular (the “**Circular**”) setting out, inter alia, (i) details of the Partial Share Exchange Offer and the information prescribed by the Listing Rules; (ii) details of the Loan Agreement and the transaction(s) contemplated thereunder; (iii) a letter from Nuada Limited containing its recommendation and advice to the board of directors of WYT in respect of the Partial Share Exchange Offer in accordance with Rule 2.4 of the Takeovers Code; and (iv) a notice of the SGM, together with a form of proxy for use at the SGM, will be despatched to WYT Shareholders on 16 September 2009.

WYT Shareholders are recommended to read the letter from Nuada Limited before deciding whether or not to vote for or against the Partial Share Exchange Offer at the SGM.

The Partial Share Exchange Offer is subject to the Conditions described in the Circular and accordingly if and when made upon fulfillment of the Pre-Conditions, it may or may not become unconditional and will lapse if it does not become unconditional. WYT Shareholders and potential investors in WYT should exercise caution when dealing in the securities of WYT.

By Order of the board of directors of
Wai Yuen Tong Medicine Holdings Limited
(位元堂藥業控股有限公司*)
Chan Chun Hong, Thomas
Managing Director

Hong Kong, 15 September 2009

As at the date of this announcement, the executive directors of WYT are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun, and the independent non-executive directors of WYT are Mr. Leung Wai Ho, Mr. Yuen Chi Choi, Mr. Siu Man Ho, Simon and Mr. Cho Wing Mou.

The directors of WYT and the Offeror jointly and severally accept full responsibility for the accuracy of the information in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.

* *For identification purpose only*